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Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), has effects beyond its antidepressant prop-
erties, altering, e.g., mechanisms involved in blood pressure and vasomotor tone control. Although many
studies have addressed the acute impact of ﬂuoxetine on the cardiovascular system, there is a paucity of
information on the chronic vascular effects of this SSRI. We tested the hypothesis that chronic ﬂuoxetine
treatment enhances the vascular reactivity to vasodilator stimuli by increasing nitric oxide (NO) signaling
and activation of potassium (Kþ) channels. Wistar rats were divided into two groups: (I) vehicle (water
for 21 days) or (II) chronic ﬂuoxetine (10 mg/kg/day in the drinking water for 21 days). Fluoxetine
treatment increased endothelium-dependent and independent vasorelaxation (analyzed by mesenteric
resistance arteries reactivity) as well as constitutive NO synthase (NOS) activity, phosphorylation of eNOS
at Serine1177 and NO production, determined by western blot and ﬂuorescence. On the other hand,
ﬂuoxetine treatment did not alter vascular expression of neuronal and inducible NOS or guanylyl cyclase
(GC). Arteries from ﬂuoxetine-treated rats exhibited increased relaxation to pinacidil. Increased acet-
ylcholine vasorelaxation was abolished by a calcium-activated Kþ channel (KCa) blocker, but not by an
inhibitor of KATP channels. On the other hand, vascular responses to Bay 41-2272 and 8-bromo-cGMP
were similar between the groups. In conclusion, chronic ﬂuoxetine treatment increases endothelium-
dependent and independent relaxation of mesenteric resistance arteries by mechanisms that involve
increased eNOS activity, NO generation, and KCa channels activation. These effects may contribute to the
cardiovascular effects associated with chronic ﬂuoxetine treatment.
& 2015 Elsevier B.V. All rights reserved.1. Introduction
Among the different classes of commercially available anti-
depressants, ﬂuoxetine, a selective serotonin reuptake inhibitor
(SSRI) approved by the Food and Drug Administration in 1987
(FDA, 2014), was the best-selling drug in the United States in 1996,
and accounted for 6 million ﬁlled prescriptions in the United
Kingdom in 2011 (Verispan, 2012). According to the National
System of Management of Controlled Products (SNGPC), 3.5 tons of
ﬂuoxetine were used in Brazil in 2006 (ANVISA, 2006), not only for
the treatment of depression, but also as an appetite suppressant
drug (Wise, 1992).reira),Side effects associated with the use of ﬂuoxetine include,
among others, orthostatic hypotension, sedation, arrhythmia and
mental confusion (Pacher et al., 2001), sexual dysfunction (Lee
et al., 2010), inappropriate secretion of anti-diuretic hormone (Liu
et al., 1996), stroke (Hung et al., 2013), gestational hypertension
and preeclampsia (Toh et al., 2009).
Crestani et al. (2011) demonstrated that chronic treatment of rats
with ﬂuoxetine increases blood pressure and alters hemodynamic
responses induced by the administration of vasoactive agents. Also,
Ribback et al. (2012) reported that different antidepressants (ami-
triptyline, tranylcypromine, and ﬂuoxetine) induce rat aortic re-
laxation regardless of the pre-contractile agent (e.g. noradrenaline or
serotonin). Mechanisms involved in the effects of these anti-
depressants include the activation of the nitric oxide (NO)/cyclic
guanosine monophosphate (cGMP)/potassium (Kþ) channels sig-
naling pathway. In addition, ﬂuoxetine has been shown to inhibit
several receptors and ion channels directly participating in the
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1997), 5-HT3 receptor (Fan, 1994) and nicotinic receptors (Maggi
et al., 1998); voltage-dependent sodium (Naþ) and Kþchannels
(Pancrazio et al., 1998; Perchenet et al., 2001; Thomas et al., 2002)
and chloride (Cl) channels (Maertens et al., 1999).
These reports clearly show that ﬂuoxetine has effects beyond
its antidepressant properties, altering mechanisms involved in
blood pressure and vasomotor tone control. Otherwise, most of the
published investigations have studied acute ﬂuoxetine effects on
the cardiovascular system. Therefore, based on this rationale, we
tested the hypothesis that chronic ﬂuoxetine treatment enhances
vascular responses mediated by NO signaling and Kþ channel
activation.2. Materials and methods
2.1. Animals
All experimental procedures performed in this study were
approved by the Ethics Committee on Animal Experiments of the
Ribeirão Preto Medical School, University of São Paulo (protocol.
013/2013) and are in accordance with the Guidelines of the Bra-
zilian College of Animal Experimentation (COBEA).
Male Wistar rats, weighing 230–250 g were used in the ex-
perimental protocols. The animals were housed in high-top-ﬁlter
cages (3 rats per cage – 48.3 cm33.725.3 cm) in a room with
controlled humidity (4575%) and temperature (2172 °C), and
light/dark cycles of 12 h. Animals had free access to food (com-
mercially available standard rat chow, Purina) and potable tap
water.
2.2. Treatment with ﬂuoxetine
Fluoxetine was administered (10 mg/kg/day) in the drinking
water, which was changed daily (Alper, 1992; Lino-de-Oliveira
et al., 2001). The average consumption of water by the rats was
monitored for three days, and the daily concentration required to
achieve a dose of 10 mg/kg/day was calculated. The bottles were
light protected to prevent degradation or oxidation of the drug.
Rats were divided randomly into two groups: (I) vehicle, water for
21 days or (II) chronic ﬂuoxetine (10 mg/kg/day for 21 days).
2.3. Vascular reactivity – isolated mesenteric resistance arteries
The method described by Mulvany and Halpern (1977) was
used. The animals were euthanized in a carbon dioxide (CO2)
chamber. Segments of third-branch mesenteric arteries, measur-
ing about 2 mm in length, were mounted in a small vessel myo-
graph (Danish Myo Tech, Model 620M, A/S, Århus, Denmark). Ar-
teries were maintained in Krebs Henseleit solution [(in mmol/L)
NaCl 130, KCl 4.7, KH2PO4 1.18, MgSO4 1.17, NaHCO3 14.9, glucose
5.5, EDTA 0.03, CaCl2 1.6], at a constant temperature of 37 °C, pH
7.4, and gassed with a mixture of 95% O2 and 5% CO2.
Mesenteric resistance artery preparations were set to reach a
tension of 13.3 kPa (kilopascal) and remained at rest for 30 min for
stabilization. The arteries were stimulated with Krebs solution
containing a high concentration of potassium [Kþ (120 mM)] to
evaluate the contractile capacity of the segments. After washing and
returning to the basal tension, arteries were pre-contracted with
phenylephrine (106 M) and then stimulated with acetylcholine
(105 M) to determine the presence of a functional endothelium.
Arteries exhibiting a vasodilator response to acetylcholine greater
than 80% were considered endothelium-intact vessels. The failure of
acetylcholine to elicit relaxation of arteries that were subjected to
rubbing of the intimal surface with human hair was taken as proofof endothelium removal. After washing and another period of sta-
bilization, concentration–response curves were performed.
2.3.1. Cumulative concentration–response curves
Mesenteric resistance arteries were stimulated with phenylephr-
ine (106–3106 M) to produce contraction (measured as an in-
crease in baseline tension). After 15 min, concentration–response
curves to acetylcholine (1010–3105 M), sodium nitroprusside
(1012–105 M), Bay 41-2272 (1010–106 M), 8-bromo-cGMP
(1010–104 M) or pinacidil (1010–104 M) were carried out.
Concentration–response curves to acetylcholine were also performed
in the presence of glibenclamide (105 M) and charybdotoxin
(107 M), inhibitors of KATP and KCa channels, respectively.
2.4. Western blot
The mesenteric bed was isolated in ice-cold Krebs solution,
cleaned from adventitial tissue and immediately frozen in liquid
nitrogen. The tissue was pulverized and homogenized in ice-cold
lysis buffer [Triton X-100 1%, 100 mM tris (pH 7.4), 100 mM sodium
pyrophosphate, 100 mM sodium ﬂuoride, 10 mM ethylene diamine
tetraacetic acid (EDTA), 10 mM sodium orthovanadate, 2 mM
phenyl methyl sulfonyl ﬂuoride (PMSF) and aprotinin 0.01 mg/ml].
The tissue extracts were centrifuged, and total protein content was
quantiﬁed using the Bradford method (Bio-Rad) (Bradford, 1976).
Proteins (40–100 μg) were then separated by electrophoresis in
polyacrylamide (SDS-PAGE) gel and transferred to nitrocellulose
membranes. Nonspeciﬁc binding sites on the membrane were
blocked with 1% bovine serum albumin (BSA) in tris-buffered
saline solution with 1% of Tween (TBS-T) for 1 h at room tem-
perature. Membranes were then incubated at 4 °C with speciﬁc
antibodies, overnight. Membranes were washed 3 times with TBS-
T and incubated with speciﬁc secondary antibodies for 1 h at room
temperature. Signals were revealed after reaction with ECL
(Amersham ECL Prime Western Blotting Detection Reagent) and
the images captured in ImageQuant 350 (GE Healthcare, Piscata
Way, NJ, USA). Results were normalized by β-actin or the total
protein and expressed relatively to the vehicle (100%) in the ex-
perimental protocols. Antibodies dilutions were used as follows:
phospho-eNOS (1:100, Cell Signaling, #9571), eNOS (1:500, Cell
Signaling, #9572), anti-guanylyl cyclase α-1 (1:1000, Abcam,
Ab50358), anti-guanylyl cyclase β (1:2000, Sigma, SAB4501344),
anti-nNOS (1:1000, Cell Signaling, #4234S), anti-iNOS (1:5000,
Sigma, N7782) and β-actin (1:3000, Cell Signaling, #2148S).
2.5. Chemiluminescence
The mesenteric bed, free from adipose tissue, was immediately
frozen in liquid nitrogen, pulverized and homogenized in 20 mM
Tris–HCl (pH 7.4). The samples were centrifuged (5000g, 10 min,
4 °C) and the total protein content was quantiﬁed using the
Bradford method (Bio-Rad) (Bradford, 1976). The samples were
analyzed in duplicate for nitrite and nitrate (NOx) using chemi-
luminescence-based assay ozone. Brieﬂy, mesenteric bed samples
were treated with cold ethanol (1:2 mesenteric bed to ethanol, for
30 min at 20 °C) and centrifuged (4000g, 10 min). NOx levels
were measured by injecting 25 μL of supernatant in a container
vent glass containing 0.8% of Vanadium (III) in HCl (1 N) at 90 °C,
which reduces NOx into NO gas. A stream of nitrogen was bubbled
through the purge vessel containing vanadium (III) with sodium
hydroxide [NaOH (1 N)], and then through an analyzer (Sievers
Nitric Oxide Analyzers 280, GE Analytical Instruments, Boulder,
CO, USA).
Fig. 1. Effects of chronic ﬂuoxetine treatment on the relaxation responses of msen-
teric resistance arteries to different agonists. Cumulative concentration-response
curves to (A) acetylcholine, an endothelium-dependent vasodilator, and (B) Sodium
Nitroprusside, an endothelium-independent vasodilators were performed in pheny-
lephrine-contracted mesenteric resistance arteries [with (A) or without
(B) endothelium] fromWistar rats chronically treated with vehicle (Veh) or ﬂuoxetine
(Fluox). Each point represents the mean7S.E.M. *Po0.05 vs. Veh, N¼6–8.
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NO production was determined by the ﬂuorescent NO indicator,
5,6 Diamino ﬂuorescein diacetate (DAF-2 DA). Mesenteric arteries
from Wistar rats were embedded in Tissue Tek O.C.T. Compound
(Sakura Finetek, Torrance, CA, USA). Unﬁxed frozen cross sections
(10 μm) were incubated with DAF-2 DA (12.5 μM; Sigma) diluted
in phosphate buffer with CaCl2 (0.4 mM); in a light protected and
humidiﬁed chamber at 37 °C for 1 h. Fluorescence was detected
with a 490–515 nm long-pass ﬁlter, under a microscope (Olympus,
BX50)with a 20 objective lens coupled to a digital camera.
Fluorescent images were analyzed by measuring the mean optical
density of the ﬂuorescence in a computer system (Image J soft-
ware) and normalized by the area.
2.7. NOS activity
The method adapted from Bredt and Snyder (1989), which
measures the conversion of [C14] arginine to [C14]-citrulline, was
used to determine NOS activity. Mesenteric bed fragments were
homogenized with 0.3 ml of Hepes buffer (pH 7.4) containing
1.25 mM CaCl2, 1 mM DTT and 1 mM tetrahydrobiopterin (BH4).
After homogenization, 1 mM NADPH, and 200,000 cpm of [C14]
arginine (270 Ci/mmol) were added and the homogenates were
incubated for 15 min at 37 °C, and centrifuged (10,000g 10 min at
4 °C). The resulting supernatants were applied to 2 ml columns of
Dowex AG WX-8 (Naþ form) and diluted with double distilled
water. The levels of [C14]-citrulline were determined using a beta
counter. This method is based on the equimolar production of NO
and citrulline from arginine, which is mediated by NOS. The re-
sults are expressed as the production of [C14]-citrulline per mg of
tissue.
2.8. Detection of superoxide anion generation
Superoxide anion generation was measured by detection of
ﬂuorescent Dihydroethidium bromide (DHE) oxidation products.
Mesenteric arteries from Wistar rats were embedded in Tissue Tek
O.C.T. Compound (Sakura Finetek, Torrance, CA, USA). Unﬁxed
frozen cross sections (10 μm) were incubated with DHE (5 μM;
polysciences) diluted in phosphate buffer with diethylene-
triaminepentaacetic acid (DTPA [100 μM]), in a light protected and
humidiﬁed chamber at 37 °C for 30 min. Fluorescence was de-
tected with a 490–515 nm long-pass ﬁlter, under a microscope
(Olympus, BX50) with a 20 objective lens coupled to a digital
camera. Fluorescent images were analyzed by measuring the mean
optical density of the ﬂuorescence in a computer system (Image J
software) and normalized by the area.
2.9. Drugs
Fluoxetine, phenylephrine, acetylcholine, sodium nitroprusside,
Bay 41-2272, pinacidil, glibenclamide, and charybdotoxin were
from Sigma-Aldrich (St. Louis, MO, U.S.A.), 8-Bromo-cGMP was
from Tocris (Ellisville, MO, U.S.A.).
2.10. Data analysis
Results are expressed as mean7standard error of the mean (S.
E.M.). Relaxation responses are expressed as the percentage of
relaxation about the levels of pre-contraction induced by pheny-
lephrine. Concentration-effect curves were analyzed by non-linear
regression using the software GraphPadPrism (GraphPad Prism
5.0, GraphPad Software Inc., San Diego, CA, USA). The potency of
agonists is expressed as pD2 (negative logarithm of the molar
concentration that produces 50% of the maximal response).Statistical analysis of the pD2 values was performed using non-
linear regression analysis followed by Student "t" test. The "t" test
was used where appropriate. The minimum acceptable level of
signiﬁcance was Po0.05.3. Results
3.1. Effects of chronic ﬂuoxetine treatment on endothelium-depen-
dent and -independent vasorelaxation
Endothelium-intact mesenteric resistance arteries from rats
chronically treated with ﬂuoxetine exhibited increased acetylcho-
line-induced relaxation [(pD2), Veh¼7.0870.07; Fluox¼7.470.11,
Po0.05] (Fig. 1A). Endothelium-denuded arteries also exhibited
signiﬁcantly increased relaxation to sodium nitroprusside [(pD2),
Veh¼7.7570.08; Fluox¼8.570.11, Po0.05] (Fig. 1B). Phenylephr-
ine-induced contraction was similar between the groups [(mN),
Veh¼24.171.7; Fluox¼23.370.9].
3.2. Effects of chronic ﬂuoxetine treatment on NO production, bioa-
vailability and NOS activity
Nitric oxide measurement, by the ﬂuorescent NO indicator
(DAF-2 DA), showed that ﬂuoxetine treatment increased both ba-
sal and acetylcholine-stimulated NO production in mesenteric
arteries [arbitrary units (A.U), Veh¼4.070.5; Fluox¼5.570.3,
and Veh¼3.170.1; Fluox¼5.570.6, respectively; Po0.05] when
compared to the vehicle group (Fig. 2A and B).
Fig. 2. Effects of chronic ﬂuoxetine treatment on NO production, bioavailability and nitric oxide synthase (NOS) activity. (A) Representative images and bar graphs showing,
(B) 5,6 Diaminoﬂuoresceindiacetate (DAF; 12.5 μM)-derived ﬂuorescence, (C) NO metabolites (NOx) levels and (D) NOS activity in mesenteric resistance arteries from Wistar
rats chronically treated with vehicle (Veh) or ﬂuoxetine (Fluox). Each point represents the mean7S.E.M. *Po0.05 vs. Veh, N¼5–7. Scale bar: 100 mm.
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[(mM/mg protein), Veh¼1.270.13; Fluox¼2.070.13, Po0.05]
(Fig. 2B) were found in mesenteric arterial bed from rats chroni-
cally treated with ﬂuoxetine (Fig. 2C). Constitutive NOS activity
was also increased in arteries from ﬂuoxetine-treated animals
when compared with the vehicle group (Fig. 2D).
3.3. Effects of chronic ﬂuoxetine treatment on eNOS phosphorylation
at Ser1177 and eNOS/nNOS/iNOS expression
Mesenteric arteries from animals chronically treated with ﬂuox-
etine exhibited increased expression of Ser1177-phosphorylated-eNOS
when compared to arteries from the vehicle group (Fig. 3A). Total
eNOS, nNOS, and iNOS expressions were similar between mesenteric
arteries from the vehicle and ﬂuoxetine groups (Fig. 3A, B, and C,
respectively).
3.4. Effects of chronic ﬂuoxetine treatment on the activation and
expression of soluble guanylyl cyclase
Bay 41-2272-induced activation of soluble guanylyl cyclase (sGC)
produced similar relaxation in arteries from the vehicle andﬂuoxetine groups [(pD2), Veh¼6.770.2; Fluox¼6.870.10]
(Fig. 4A). Expression of sGC α and β subunits was similar between
arteries from vehicle and ﬂuoxetine-treated rats (Fig. 4B).
3.5. Effects of chronic ﬂuoxetine treatment on the relaxation re-
sponses to 8-bromo-cGMP and pinacidil
Relaxation responses of the mesenteric resistance arteries to
the cGMP analog, 8-bromo-cGMP, were similar between the
groups [(pD2), Veh¼4.570.4; Fluox¼4.470.3] (Fig. 5A). How-
ever, pinacidil-induced vasorelaxation was signiﬁcantly increased
in animals treated with ﬂuoxetine when compared to the vehicle
group [(pD2), Veh¼5.970.12; Fluox¼6.570.17, Po0.05] (Fig. 5B).
3.6. Effects of KATP and KCa channels blockers on the increased
acetylcholine vasorelaxation induced by chronic ﬂuoxetine treatment
Relaxation responses to acetylcholine were not modiﬁed in the
presence of KATP channel blocker, glibenclamide. In other words,
acetylcholine vasorelaxation was signiﬁcantly increased in animals
treated with ﬂuoxetine when compared to the vehicle group
[(pD2), Veh¼7.670.11; Fluox¼8.070.12, Po0.05] (Fig. 6A).
Fig. 3. Effects of chronic ﬂuoxetine treatment on eNOS phosphorylation at Ser1177 and
eNOS, nNOS, and iNOS expression. On top, representative western blot images and at
the bottom, bar graphs showing the densitometric analyses of (A) phosphorylated and
total endothelial nitric oxide synthase (eNOS), (B) neuronal nitric oxide synthase
(nNOS), (C) inducible nitric oxide (iNOS) expression in mesenteric arterial bed from
Wistar rats chronically treated with vehicle (Veh) or ﬂuoxetine (Fluox). Each column
represents the mean7S.E.M. *Po0.05 vs. Veh, N¼3–4.
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in acetylcholine vasorelaxation between the groups [(pD2),
Veh¼7.370.15; Fluox¼7.470.12] (Fig. 6B).
3.7. Effects of chronic ﬂuoxetine treatment on superoxide anion
generation
Chronic ﬂuoxetine treatment did not change superoxide anion
generation in mesenteric arteries when compared with the vehiclegroup [(A.U.), Veh¼30.873.0; Fluox¼31.771.5] (Fig. 7).4. Discussion
The major ﬁndings of the present investigation about the
chronic ﬂuoxetine effects on vascular reactivity are: (1) Fluoxetine
treatment increases endothelium-dependent and -independent
vasorelaxation as well as the constitutive NO synthases (eNOS and
nNOS) activity, the phosphorylation of eNOS at Serine1177 and, the
NO production; (2) Fluoxetine does not change vascular expres-
sion of neuronal and iNOS or guanylyl cyclase (GC); (3) Vasor-
elaxation induced by pinacidil, an activator of ATP-sensitive Kþ
channels, is increased in arteries from ﬂuoxetine-treated rats;
(4) Vasorelaxations induced by a cGMP analog or a sGC activator
were not affected; and (5) blockade of KCa channels abolishes in-
creased vasorelaxation. These data indicate that chronic ﬂuoxetine
treatment increases the relaxation of resistance arteries by me-
chanisms that involve increased constitutive NOS activity, NO
generation and activation of KCa channels. The following discus-
sion intends to cover all these data.
To determine whether chronic ﬂuoxetine treatment changes
mechanisms involved in the vasomotor tone control, we initially
assessed vascular reactivity to acetylcholine, an endothelium-de-
pendent agonist, and to sodium nitroprusside, an endothelium-
independent agent. Mesenteric arteries from rats chronically
treated with ﬂuoxetine exhibited increased vasodilator responses
to both agents. One of the mechanisms that could facilitate acet-
ylcholine and sodium nitroprusside-induced vasorelaxation is an
increased activation of the NO-GC-cGMP pathway. The enzyme
sGC contains a ferrous heme heterodimer composed of α and β
subunits, which is activated in response to NO binding to the heme
moiety (Meurer et al., 2009). NO-induced activation of sGC en-
zyme in vascular smooth muscle cells increases intracellular cGMP
levels, leading to activation of cGMP-dependent kinases (PKG),
reduction of intracellular Ca2þ levels, activation of Kþ channels
and relaxation (Vanhoutte, 1989).
To evaluate whether ﬂuoxetine changes the NO-GC-cGMP sig-
naling pathway, we determined the vascular effects of a cGMP
analogous and a GC activator, but no differences in the vascular
responses to these agents were observed. Similarly, there were no
differences in the vascular expression of sGC α and β subunits
between the groups. Together, these data suggest that chronic
ﬂuoxetine treatment does not increase NO-GC-cGMP signaling.
As already mentioned, Ribback and colleagues (2012) demon-
strated that NO-cGMP signaling is an important mechanism of
ﬂuoxetine and other SSRIs to promote acute vascular relaxation in
vitro since NOS and cGMP inhibitors decreased relaxation to these
drugs. Also, Kþ channel activation contributes to ﬂuoxetine- and
SSRIs-induced vasorelaxation. NO-induced activation of Kþ chan-
nels and the consequent hyperpolarization and vasorelaxation
may occur indirectly, via cGMP (Jackson, 2005), but also directly
and independently of cGMP, as demonstrated by Bolotina et al.,
(1994). Accordingly, NO has been shown to activate directly KCa
and KATP channels (Kawano et al., 2009).
Our results indicate that ﬂuoxetine does not alter mechanisms
associated with GC activation and cGMP-induced responses, but it
changes responses mediated by activation of Kþ channels. Also,
arteries of rats chronically treated with ﬂuoxetine exhibited in-
creased relaxant responses to pinacidil suggesting that increased
relaxation to acetylcholine and sodium nitroprusside are due to
increased Kþ channels activation. To conﬁrm this hypothesis we
determined the inhibitors of KATP and KCa channels effects on
acetylcholine vascular reactivity. Increased dilation to acetylcho-
line in arteries from ﬂuoxetine-treated rats was only abolished by
charybdotoxin, a KCa blocker. This result was initially unexpected
Fig. 4. Effects of chronic ﬂuoxetine treatment on vasorelaxation induced by GC stimulation and on soluble guanylyl cyclase expression. (A) Cumulative concentration-
response curves to Bay 41-2272, a stimulator of sGC, in phenylephrine-contracted mesenteric resistance arteries [with endothelium] fromWistar rats chronically treated with
vehicle (Veh) or ﬂuoxetine (Fluox). (B) Bar graphs show the densitometric analysis of GCα and GCβ expression. On the top, representative western blot images and at the
bottom, bar graphs indicating the ratio of GCα/β-actin and GCβ/β-actin, respectively. Each point represents the mean7S.E.M. *Po0.05 vs. Veh, N¼3–4.
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increased relaxation to pinacidil, an activator of KATP channels.
However, this result would suggest the possibility of nonspeciﬁc
activation of Kþ channels by pinacidil. Accordingly, Gelband and
McCullough (1993) demonstrated that pinacidil increases the
opening probability of single KCa channels in rabbit aortic smooth
muscle microsomes.
By using activators and inhibitors of Kþ channels to identify
mechanisms associated with ﬂuoxetine-induced dilatation in
skeletal muscle arteries, Pacher et al. (1999a, 1999b) concluded
that Kþ channels activation is not involved in ﬂuoxetine-induced
vasorelaxation. Also, ﬂuoxetine has also been reported to block Kþ
channels (Park et al., 1999; Perchenet et al., 2001). It is important
to mention that the studies by Pacher (1999a, 1999b), Perchenet
(2001), Park (1999) and colleagues tested acute effects of ﬂuox-
etine. It is possible that whereas Kþ channels are not activated (or
are blocked) by acute administration of ﬂuoxetine, chronic treat-
ment with this SSRI leads to increased Kþ channels function.
Fluoxetine and others SSRIs, such as paroxetine, increase NOx
(NO metabolites) levels, an additional mechanism that may con-
tribute to the increased vasodilator responses in the ﬂuoxetine-
treated group. In the present study, increased NO production in
the mesenteric bed of rats chronically treated with ﬂuoxetine was
determined by an NO-sensitive ﬂuorescent probe and NOx levels.
Supporting our data, Chrapko and colleagues (2006) demonstrated
that treatment for eight weeks with paroxetine, an SSRI, increased
NOx plasma levels in healthy subjects and patients with the major
depressive disorder. Also, Ikenouchi-Sugita et al., (2009) observed
increased NOx plasma levels in patients with major depressivedisorder treated for 4 or 8 weeks with milnacipran, a serotonin-
norepinephrine reuptake inhibitor (SNRI). Increased NOx levels
after ﬂuoxetine treatment seem to be a time-dependent event,
since as demonstrated by Krass and colleagues (2011) a single dose
of ﬂuoxetine is unable to promote changes in the brain NOx levels.
To investigate mechanisms involved with the increased NO
generation, we determined the expression of total and phos-
phorylated eNOS. The western blot analysis showed increased
eNOS phosphorylation at Ser1177 in mesenteric resistance arteries
of rats treated with ﬂuoxetine.
Ofek et al. (2012) reported that endothelial cells incubated with
ﬂuoxetine exhibit increased eNOS phosphorylation and greater
interaction with heat shock protein 90 (HSP90), a protein known
to regulate trafﬁcking and signaling of several other proteins.
Garcia-Cardena et al. (1998) demonstrated that HSP90 association
with eNOS increases NO production. More importantly, HSP90/
eNOS interaction is increased after chronic ﬂuoxetine treatment.
NOS activity was also determined to conﬁrm these results. Our
ﬁndings show that constitutive NOS activity is increased in the
mesenteric bed of ﬂuoxetine-treated rats when compared with the
control group. Contrary to our ﬁndings, Chrapko et al. (2006) did
not observe changes in platelets NOS activity after paroxetine
treatment, indicating that tissue-speciﬁc differences may account
for the apparent discrepancy.
The above-mentioned data, along with the absence of sig-
niﬁcant differences in nNOS and iNOS expression between arteries
from vehicle- and ﬂuoxetine-treated rats, indicate that increased
eNOS phosphorylation and increased eNOS-derived NO generation
contributes to the vascular changes observed with chronic
Fig. 5. Effects of chronic ﬂuoxetine treatment on the vasorelaxation response to the
cGMP analog 8-bromo-cGMP and a KATP channel activator. Cumulative concentra-
tion–response curves to (A) 8-bromo-cGMP and (B) pinacidil in phenylephrine-
contracted mesenteric resistance arteries [with endothelium] from Wistar rats
chronically treated with vehicle (Veh) or ﬂuoxetine (Fluox). Each point represents
the mean7S.E.M. *Po0.05 vs. Veh, N¼5.
Fig. 6. Effects of KATP and KCa channels blockers on the increased acetylcholine
vasorelaxation induced by chronic ﬂuoxetine treatment. Cumulative concentra-
tion–response curves to acetylcholine in the absence and in the presence of
(A) glibenclamide, a KATP channel blocker, and (B) charybdotoxin, a KCa channel
blocker, in phenylephrine-contracted mesenteric resistance arteries [with en-
dothelium] from Wistar rats chronically treated with vehicle (Veh) or ﬂuoxetine
(Fluox). Each point represents the mean7S.E.M. *Po0.05 vs. Veh, N¼5–6.
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(2015) did not observe changes in nNOS or iNOS expression after
ﬂuoxetine treatment.
From a clinical point of view, many patients with depression
also exhibit cardiovascular diseases (Mast et al., 2004; Rabkin
et al., 1983). Reduced NO biosynthesis or bioavailability has been
considered a potential mechanism to explain this correlation
(Joynt et al., 2003). Reduction of NO bioavailability and eNOS ac-
tivity or decreased responsiveness of vascular smooth muscle cells
to NO are common mechanisms described in cardiovascular dis-
eases, such as arterial hypertension (Hayakawa and Raij, 1998;
Luscher et al., 1987). The increased NO generation induced by
ﬂuoxetine may be a potential advantage in the depression treat-
ment this disorder is associated with cardiovascular diseases (Lara
et al., 2003). Some antidepressants, such as imipramine or venla-
faxine, decrease NOx levels in the brain (Krass et al., 2011). It is
possible that beneﬁcial effects of ﬂuoxetine may be related to
opposite effects on NOx levels.
Its antioxidant properties represent another potential me-
chanism involved in ﬂuoxetine-induced increased NO bioavail-
ability. To test this evidence, DHE ﬂuorescence, a technique that
detects superoxide anion generation, was determined in mesen-
teric arteries sections. No differences in DHE ﬂuorescence, or su-
peroxide anion generation, were observed between the groups.
Galecki et al. (2009) demonstrated that ﬂuoxetine therapy at-
tenuates oxidative stress, i.e. it increases the activity of antioxidative
enzymes, in patients with major depressive disorder. It is important
to note that these patients already presented a pro-oxidative status
before the treatment was started. Similarly, Chung et al. (2010)
observed antioxidant effects with ﬂuoxetine treatment in thepresence of inﬂammatory conditions, suggesting that ﬂuoxetine
effectively has antioxidant properties in oxidative stress-associated
conditions. Since no differences in superoxide anion generation
were observed after chronic treatment of healthy animals with
ﬂuoxetine, one may suggest that ﬂuoxetine does not have sig-
niﬁcant antioxidative effects when reactive oxygen species pro-
duction is normal/balanced.
In summary, chronic ﬂuoxetine treatment increases en-
dothelium-dependent and -independent relaxant responses in
mesenteric resistance arteries by mechanisms that involve in-
creased eNOS activity, NO generation, and KCa channels activation.
Whether these effects contribute to the side effects of the cardi-
ovascular system or whether this may represent a beneﬁcial effect
associated with chronic ﬂuoxetine treatment needs to be further
investigated. It is important to emphasize, once again, that the aim
of the investigation was to study the effects of chronic ﬂuoxetine
use in vascular reactivity. Since these effects were determined only
in arteries from the mesenteric circulation, further studies in other
vascular beds are necessary.Authors' contributions
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